IGF-1 LR3 / BPC-157 Blend
Also known as: IGF-1 LR3 + BPC-157 Blend
A research blend combining the long-acting growth factor IGF-1 LR3 with the cytoprotective peptide BPC-157 to support anabolic growth and tissue repair. It is studied for muscle growth, recovery, and injury healing.
Last updated
Mechanism of Action
IGF-1 LR3 is a modified analog of insulin-like growth factor 1 with an Arg substitution at position 3 and a 13-amino-acid N-terminal extension, which markedly reduces its binding to IGF-binding proteins and extends its half-life. It activates the IGF-1 receptor and downstream PI3K/Akt/mTOR and MAPK pathways to drive protein synthesis, cell proliferation, and hypertrophy. BPC-157 complements this by promoting angiogenesis through VEGFR2 signaling, activating the nitric oxide system, and enhancing fibroblast migration and growth-factor receptor expression for tendon and soft-tissue repair. The blend pairs potent anabolic signaling with cytoprotective, angiogenic repair.
- Half-life
- IGF-1 LR3 is extended to roughly 20-30 hours due to reduced binding-protein affinity, while BPC-157 is short-lived (minutes to a few hours).
- Administration Routes
- subcutaneous
- Research Status
- Research Chemical
Reported Benefits
- Drives protein synthesis and muscle hypertrophy via IGF-1R signaling
- Supports angiogenesis and soft-tissue repair from BPC-157
- Studied for accelerated injury and tendon healing
- May enhance recovery and lean-mass gains
- Combines anabolic and cytoprotective mechanisms
- Long-acting IGF analog provides extended receptor activity
Potential Side Effects
- Hypoglycemia from IGF-1 receptor and insulin cross-activity
- Localized tissue growth at injection sites
- Injection-site irritation
- Lightheadedness or fatigue
- Theoretical concern for promoting abnormal cell growth with chronic use
Common Dosing
For research use only and not medical advice; literature describes IGF-1 LR3 in the ~20-50 mcg daily range and BPC-157 in the ~250-500 mcg range one to two times daily. The blend has no standardized human protocol.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Active or suspected malignancy due to potent growth-promoting activity
- Pregnancy and breastfeeding
- Diabetes or hypoglycemia risk without monitoring
IGF-1 LR3
IGF-1 LR3 (Long R3 IGF-1) is an engineered, long-acting analog of insulin-like growth factor 1 studied for sustained anabolic and tissue-growth signaling. Its modifications give it a far longer half-life than native IGF-1.
BPC-157
A synthetic peptide fragment derived from a protein found in gastric juice, studied for its broad tissue-healing and cytoprotective effects. Popular in research for tendon, ligament, muscle, and gut repair.
TB-500
A synthetic version of the active region of Thymosin Beta-4, a naturally occurring peptide that regulates cell migration and tissue repair. Researched for recovery, flexibility, and wound healing.
MGF (Mechano Growth Factor)
MGF is a splice variant of IGF-1 produced locally in muscle in response to mechanical loading or damage. It is studied for its role in activating muscle stem cells and supporting tissue repair.
IGF-1 DES
IGF-1 DES is a truncated variant of insulin-like growth factor 1 missing the first three N-terminal amino acids, studied for potent, localized anabolic and tissue-growth effects. It is noted for higher activity at the site of injection.
- View
Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency
1992
- View
Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats
1993
- View
Insulin-like growth factor-I (IGF-I) analogue, LR(3)IGF-I, ameliorates the loss of body weight but not of skeletal muscle during food restriction
2001
- View
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat
2010